摘要
Abstract
Objective To observe the effect of valsartan combined with alprostadil on chronic glomerulonephritis and its effect on cytokines.Methods Sixty patients with chronic glomerulonephritis from April-2015 to September 2016 treated in Department of Nephrology,Hubei Provincial Hospital of Traditional Chinese and Western Medicine were enrolled.Those pa-tients were divided into the control group and the observation group according to different treatment methods.The control group,patients were treated with valsartan 80 mg orally at 1 day.The observation group in the control group based on the treatment of alizarin injection 10 μg with saline 100 mg intravenous infusion,1 /d,two groups was treated for 40 days.Ob-served the levels of IgM,IgG,IgA,C3,24 hour urinary protein excretion,serum creatinine,urea nitrogen and VEGF, Cys C,IL-2 before and after treatment.Results After treatment, the total effective rate of the observation group was 96.67%higher than the control group 76.67%(P <0.05).Comparison of two groups after treatment,24 hours urinary protein ex-cretion(t =4.750,P =0.000);Serum creatinine(t =3.511,P =0.000);Urea nitrogen(t =7.373,P =0.000),the difference was significant(P <0.05).Comparison of two groups after treatment,IgM(t =6.214,P =0.000),IgG(t =6.205,P =0.000),IgA(t =6.472,P =0.000), C3(t =4.899,P =0.000), the difference was significant(P <0.05).The levels of VEGF, Cys C and IL-2 in the observation group were compared with the control group[(386.28 ± 60.44)pg/ml vs.(426.57 ±70.55)pg/ml;(0.65 ±0.06)mg/L vs.(1.01 ±0.14)mg/L;(3.25 ±0.51)ng/ml vs. (2.42 ±0.28)ng/ml]significantly different(t =2.375,12.945,7.813,P <0.05).Conclusion Valsartan combined with alprostadil can effectively treat patients with chronic glomerulonephritis,which can significantly reduce renal function,enhance the immune function level,compared with a single valsartan treatment effect is more significant.关键词
缬沙坦/前列地尔/肾小球肾炎,慢性/血管内皮生长因子/胱抑素C/白介素-2Key words
Valsartan/Alprostadil/Glomerulonephritis,chronic/Vascular endothelial growth factor/Cystatin C/Inter-leukin-2
